News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Thorvardur Halfdanarson: Cabozantinib in previously treated advanced NETs
Thor Halfdanarson/mayoclinic.org
Sep 19, 2024, 18:53

Thorvardur Halfdanarson: Cabozantinib in previously treated advanced NETs

Thorvardur Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X:

“Hot off the press, Alliance CABINET!

Cabozantinib in previously treated (93% had SSA, 60% had PRRT, 72% had everolimus) advanced NETs.

The primary endpoint, PFS, was significantly better in the cabo arm than placebo.”

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

Authors: Jennifer A. Chan, Susan Geyer, Tyler Zemla, Michael V. Knopp, Spencer Behr, Sydney Pulsipher,Fang-Shu Ou, Ph.D., Amylou C. Dueck, Jared Acoba, Ardaman Shergill, Edward M. Wolin, Thorvardur R. Halfdanarson, Bhavana Konda, Nikolaos A. Trikalinos, Bernard Tawfik, Nitya Raj, Shagufta Shaheen, Namrata Vijayvergia, Arvind Dasari, Jonathan R. Strosberg,  Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly and Jeffrey A. Meyerhardt.

 

Thorvardur Halfdanarson: Cabozantinib in previously treated advanced NETs

Source: Thor Halfdanarson/X

Alliance for Clinical Trials in Oncology Amylou C. Dueck Ardaman Shergill Arvind Dasari Bernard Tawfik Bhavana Konda cancer cancer awareness cancer treatment Edward M. Wolin Eileen M. O'Reilly Elise C. Kohn Fang-Shu Ou fight against cancer Global fight against cancer Jared Acoba Jeffrey A Meyerhardt Jennifer A. Chan Jonathan R. Strosberg Matthew H. Kulke Michael V. Knopp Namrata Vijayvergia Nikolaos A. Trikalinos Nitya Raj OncoDaily Oncology Ph.D Shagufta Shaheen Spencer Behr Susan Geyer Sydney Pulsipher Thor Halfdanarson Thorvardur Halfdanarson Tyler Zemla
Special Coverage
Science
Jan 20, 2025, 16:03
Amy Moore: Biomarker testing can help identify actionable mutations in patients with squamous NSCLC
Insight
Jan 20, 2025, 16:03
Navneet Singh: Ensuring global access to the 3 'A's of treatment
Blog
Jan 20, 2025, 15:56
Erman Akkus: Downstaging of HCC before liver transplantation
Blog
Jan 20, 2025, 15:45
Chris Weight: Accepting applications for the Cleveland Clinic Urology, Society of Urologic Oncology fellowship program
Blog
Jan 20, 2025, 15:41
Endoscopic Ultrasound Gastroenterostomy versus Duodenal Stenting for Malignant GOO
Science
Jan 20, 2025, 15:25
Tony Hung: A virtual integrative medicine program to improve symptoms and decrease hospitalization
Blog
Jan 20, 2025, 14:46
Gregg Margolis: Three things to read about health policy this week
Blog
Jan 20, 2025, 14:43
Afreen Shariff: Excellent to connect with fellow board members at the ACCC
Dialogues
Jan 20, 2025, 14:32
The Current Situation with Colorectal Cancer in Kazakhstan
Science
Jan 20, 2025, 14:17
Hung Trinh: Bispecific Antibodies in Cancer Therapy
Insight
Jan 20, 2025, 14:16
Amy Moore: Ensuring that all patients benefit from recent scientific advances in lung cancer
Blog
Jan 20, 2025, 14:04
Emily Drake: I finally joined Bluesky